Evidence map›Paper›PMID 27604908›Full record

ArticleZeitschrift fur Rheumatologie2018

New inflammatory markers in early rheumatoid arthritis.

O Zengin, M E Onder, A Kalem, M Bilici, I H Türkbeyler, Z A Ozturk, B Kisacik, A M Onat

Abstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. [Epidemiological profile of rheumatoid arthritis].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

O ZenginSchool of Medicine, Department of Rheumatology, Gaziantep University, 27500, Gaziantep, Turkey. drorhanzengin@gmail.com.
M E OnderSchool of Medicine, Department of Rheumatology, Gaziantep University, 27500, Gaziantep, Turkey.
A KalemSchool of Medicine, Department of Internal Medicine, Gaziantep University, 27500, Gaziantep, Turkey.
M BiliciSchool of Medicine, Department of Internal Medicine, Gaziantep University, 27500, Gaziantep, Turkey.
I H TürkbeylerSchool of Medicine, Department of Geriatrics, Gaziantep University, 27500, Gaziantep, Turkey.
Z A OzturkSchool of Medicine, Department of Geriatrics, Gaziantep University, 27500, Gaziantep, Turkey.
B KisacikSchool of Medicine, Department of Rheumatology, Gaziantep University, 27500, Gaziantep, Turkey.
A M OnatSchool of Medicine, Department of Rheumatology, Gaziantep University, 27500, Gaziantep, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is the most common chronic inflammatory disorder and is associated with progressive destruction of synovial joints and physical disability. Therapies with known benefits include disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, as well as more recent biologic agents, such as tumor necrosis factor inhibitors (anti-TNF therapy).

methodThis was a retrospective study, which included 205 RA and 112 early RA (ERA) patients from the Rheumatology Clinic at Gaziantep University School of Medicine Research Center as well as 104 healthy controls.

resultsThe mean neutrophil to lymphocyte ratio (NLR) was found to be 3.15 ± 2.64 in the patient group and 2.03 ± 0.94 in the control group. The mean platelet to lymphocyte ratio (PLR) was 162.39 ± 107.76 in the patient group and 131.23 ± 48.09 in the control group. There was a significant difference in both the NLR and PLR between the patient and control groups (both p < 0.01). There was a significant difference in both the NLR and PLR between patients with active disease and remission (both p < 0.001) in RA, including anti-TNF therapy and DMARDs groups. There was a significant difference in NLR (p = 0.001) but not in PLR (p = 0.051) between active disease and remission in ERA.

conclusionThe results of the present study suggest that the NLR may be considered a useful marker of disease activity in RA and one that can aid the diagnosis of ERA. The PLR can be used in the assessment of disease activity in RA patients undergoing anti-TNF therapy but is not suitable for diagnosing ERA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiomarkersAdultFemaleHumansInflammationLymphocytesMaleMiddle AgedRetrospective StudiesTumor Necrosis Factor-alphaAntirheumatic AgentsBiomarkersTumor Necrosis Factor-alphaBiomarkersDisease modifying antirheumatic drugsInflammationLymphocytesTumor necrosis factor

Identifiers

PMID27604908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.